Mirova, acting on behalf of funds under its management, has declared to the AMF that on September 26 it exceeded the threshold of 5% of voting rights in MedinCell, following the acquisition of shares on the market.

The declarant stated that it held 2,055,476 MedinCell shares representing the same number of voting rights, i.e. 7.07% of the capital and 5.01% of the voting rights of this pharmaceutical company specializing in long-acting injectable products.

Copyright (c) 2024 CercleFinance.com. All rights reserved.